8-K: CV Sciences Reports Q2 2025 Financial Turnaround

CV Sciences, Inc. announced its second quarter 2025 financial results, reporting a decrease in revenue but significant improvements in gross margin and adjusted EBITDA.

Summary

• Revenue for the second quarter 2025 was $3.6 million, an 8% decrease from $4.0 million in the second quarter 2024, but flat compared to $3.6 million in the first quarter 2025.
• Gross margin reached 50.9% for the second quarter 2025, up from 47.0% in Q2 2024 and 46.0% in Q1 2025, marking the highest gross margin since the third quarter 2019.
• Cash balance increased to $0.9 million at quarter end, compared to $0.5 million at the end of 2024.
• Recognized positive adjusted EBITDA of $0.1 million for the second quarter 2025, a significant improvement from an adjusted EBITDA loss of $6,000 in Q2 2024 and $0.3 million in Q1 2025, representing the first positive adjusted EBITDA since the second quarter 2019.
• Operating loss improved to $0.1 million in Q2 2025, down from $0.6 million in Q2 2024, primarily due to reduced selling, general, and administrative expenses.
• The decline in sales was primarily due to lower sales volume, with units sold decreasing by 7.0% and average sales prices decreasing by 2.8% year-over-year, attributed to state regulatory pressure.
• New products launched since January 1, 2023, contributed 39% of net revenue for the second quarter 2025, with 34 new products introduced during this period.

Sentiment

Score: 7

Explanation: Despite a slight revenue decline, the company demonstrated strong operational improvements, achieving its highest gross margin in 23 quarters and its first positive adjusted EBITDA in six years. Reduced operating losses and increased cash balance indicate effective cost management and a positive trajectory towards consistent profitability, although regulatory challenges remain.

Positives

• Gross margin improved significantly to 50.9% in Q2 2025, the highest achieved in the last 23 quarters, indicating enhanced operational efficiency.
• Achieved positive adjusted EBITDA of $0.1 million in Q2 2025, marking the first positive adjusted EBITDA since Q2 2019, demonstrating progress towards profitability and cost-efficient execution.
• Cash balance increased to $0.9 million at quarter-end from $0.5 million at the end of 2024, improving liquidity.
• Operating loss was substantially reduced to $0.1 million in Q2 2025 from $0.6 million in Q2 2024, primarily due to effective cost management and reduced selling, general, and administrative expenses.
• New product development has been successful, with 39% of Q2 2025 net revenue derived from 34 new products launched since January 1, 2023, indicating successful diversification efforts.

Negatives

• Revenue decreased to $3.6 million in Q2 2025 from $4.0 million in Q2 2024, an 8% year-over-year decline.
• Sales volume decreased by 7.0% and average sales prices decreased by 2.8% year-over-year, primarily due to state regulatory pressure on the CBD category.
• Reported a net loss of $(0.261) million for Q2 2025, although an improvement from $(0.584) million in Q2 2024, the company is not yet consistently profitable on a GAAP basis.

Risks

• The company faces challenges from an uncertain state and federal regulatory environment for the CBD category, which has impacted sales volume.
• Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict, with actual outcomes potentially differing materially.

Future Outlook

Management anticipates further gross margin improvements in the second half of 2025. The company is working diligently to achieve organic growth through new product development and continues to pursue additional M&A opportunities to improve top-line revenue, profitability, and cash flow. In-sourcing production through the Elevated Softgels acquisition is expected to further improve gross margin over time. Continuous commitment to innovation will diversify the product offering and help mitigate challenges from the uncertain regulatory environment for CBD.

Management Comments

• "We are pleased with our second quarter 2025 results."
• "Our gross margin of 50.9% in the second quarter 2025 is our best gross margin in the last 23 quarters."
• "We anticipate further gross margin improvements in the second half of 2025."
• "We are working diligently to achieve organic growth through new product development while continuing to pursue additional M&A opportunities to improve our top-line revenue, profitability and cash flow."
• "We generated our first positive adjusted EBITDA since the second quarter of 2019, which demonstrates our cost-efficient execution as we move closer to profitability and positive cash flow on a consistent basis."
• "We are also making good progress on in-sourcing production of many of our current products through our acquisition of Elevated Softgels, which will help to further improve our gross margin over time."
• "Our continuous commitment to innovation will diversify our product offering and help mitigate some of the challenges we face with the uncertain state and federal regulatory environment for the CBD category."
• "We look forward to a more balanced product portfolio through further new product development and M&A opportunities that will help to improve our top-line revenue, profitability and shareholder value."

Industry Context

The company operates in the consumer wellness sector, with a core focus on hemp extracts (CBD) and a strategic expansion into other nutraceuticals and plant-based foods. The filing highlights significant challenges from an 'uncertain state and federal regulatory environment for the CBD category,' which has directly impacted sales volume. In response, the company is actively diversifying its product portfolio and pursuing M&A opportunities, indicating a strategic pivot to reduce reliance on the volatile CBD market and align with broader trends towards diversified natural health and wellness products.

Legal Proceedings

• Professional fees were incurred during 2024 associated with a legal dispute with a founder.

Stakeholder Impact

• Shareholders: Potential for improved profitability and shareholder value through strategic initiatives like M&A and new product development, despite current revenue challenges.
• Customers: Benefit from a diversified product offering and continuous innovation, providing a broader range of wellness products.
• Employees: Continued operations and strategic growth initiatives may provide stability and future opportunities.
• Suppliers: The company's move to in-source production through the Elevated Softgels acquisition may impact relationships with existing external manufacturers.

Next Steps

• Achieve further gross margin improvements in the second half of 2025.
• Pursue organic growth through new product development.
• Pursue additional M&A opportunities to improve top-line revenue, profitability, and cash flow.
• Continue in-sourcing production of current products through the Elevated Softgels acquisition to further improve gross margin over time.
• Diversify product offering through continuous innovation to mitigate challenges from the uncertain state and federal regulatory environment for the CBD category.
• Host a conference call and webcast on August 13, 2025, to discuss these results.

Key Dates

Recommendation

The company demonstrated strong operational efficiency with its highest gross margin in 23 quarters and achieved its first positive adjusted EBITDA since Q2 2019, indicating effective cost control and a move towards profitability. However, the 8% year-over-year revenue decline, primarily due to state regulatory pressure on CBD, presents a significant headwind. While strategic initiatives like new product development and M&A are underway to diversify and grow, the uncertain regulatory environment for the core CBD business warrants a cautious approach. Investors should hold to observe if the positive operational trends translate into consistent revenue growth and sustained profitability amidst industry challenges.

Keywords

CBD, Hemp Extracts, Nutraceuticals, Consumer Wellness, Financial Results, Earnings, Quarterly Report, Adjusted EBITDA, Gross Margin, Revenue, OTCQB:CVSI